INTRODUCTION
============

Endovascular treatment for cerebral aneurysm has been remarkably developed. Stent assisted coiling (SAC) for complex aneurysm has been considered as the standard treatment. Intracranial stent for cerebral aneurysm is designed as a self-expanding type that can improve angiographic aneurysmal occlusion by serving as a scaffold to prevent coil prolapse. It can also enhance coil packing density and provide great stability to the coil mass while preventing recanalization \[[@b7-jkns-2019-0087]\]. However, in-stent stenosis (ISS) as delayed complication of this procedure has been reported. Some characteristics of them have been suggested by previous studies \[[@b4-jkns-2019-0087],[@b9-jkns-2019-0087],[@b12-jkns-2019-0087],[@b13-jkns-2019-0087],[@b17-jkns-2019-0087],[@b18-jkns-2019-0087],[@b24-jkns-2019-0087],[@b25-jkns-2019-0087]\]. These suggestions had limitations in that these studies had small numbers of cases with short-term follow up. In addition, most articles only considered high degree stenosis (\>50%) as meaningful ISS \[[@b9-jkns-2019-0087],[@b12-jkns-2019-0087],[@b13-jkns-2019-0087],[@b18-jkns-2019-0087]\]. The pathophysiology of ISS is not well-known yet, although endothelial injury following stent deployment, allergy to metal stent components, ingrowth of endothelium, and intimal ingrowth have been considered as potentially putative factors \[[@b5-jkns-2019-0087]\]. Additionally, we believe that medical factors such as metabolic syndrome, smoking, and other factors could be related to ISS formation. Thus, the objective of this study was to evaluate long-term radiologic prognosis and characteristics of ISS after SAC for cerebral aneurysm and analyze its risk factors.

MATERIALS AND METHODS
=====================

Study population
----------------

This retrospective study was approved by the Institutional Review Board of our hospital (2019-04-020). Due to the retrospective design of the study, consent was neither required by the IRB nor by the study team. Radiological records of 362 cases of SAC between March 2007 and December 2016 were retrospectively reviewed. Patients were included in this study if they had follow-up angiogram using catheter selected angiography at least twice. Patients were excluded if they were treated with a flow-diverter or they only had follow-up angiography within 12 months or no radiological follow-up. Of 120 patients, 123 aneurysms were enrolled. Patient data including age, sex, aneurysm size, neck size, procedural complication, kinds of stent, ISS associated symptom, ruptured state, location of ISS, degree of ISS, radiologic prognosis of ISS, follow-up period of time, and medical comorbidities such as hypertension, diabetes mellitus (DM), dyslipidemia, and smoking were collected.

Procedure and medication
------------------------

We have performed stent assisted coil embolization when ratio of dome to neck was above 2 or it was difficult to make a stable frame by coiling alone. At the beginning of the procedure, a bolus of 5000 IU of heparin was administered after insertion of an introducer sheath followed by 1000 IU/hour of heparin. The stent was deployed such that distal markers were placed more distally from the arising portion of neck and sac. Neuroform 2 or Neuroform 3 stent (Boston Scientific, Marlborough, MA, USA), Neuroform EZ (NF; Stryker, Cork, Ireland), and Enterprise (EP; Codman, West Chester, PA, USA) were used. Coil embolization was mainly performed with the introduction of a microcatheter through the cell of stent. Bare platinum coils used included Guglielmi detachable coil (Boston Scientific), Target coil (Stryker), and MicroPlex coil (MicroVention, Aliso Viejo, CA, USA). For unruptured cases, pretreatment with dual antiplatelet therapy (100 mg aspirin and 75 mg clopidogrel per oral) was performed for five to seven days. Dual antiplatelet therapy (75 mg clopidogrel daily and 100 mg aspirin daily indefinitely) was started one day later after the procedure was completed. For ruptured cases, instead of using dual antiplatelet therapy, intravenous aspirin lysine 500 to 900 mg was injected immediately after the first coil deployment following stenting. Activated clotting time was maintained between 250 and 300 seconds as in usual cases. Dual antiplatelet therapy (same prescription as above) was started the next day after treatment.

Follow-up protocol
------------------

Our protocol of angiographic follow-up using only catheter selected angiography was described as follows. The first angiographic follow-up was conducted at 3 to 6 months postoperatively according to clinical outcome and immediate angiographic results. The next one was performed at 12 months later depending on angiographic results of the first follow-up. The third one was performed at 12 to 24 months later depending on results of the second follow-up. All subjected were followed up from 12 months to over 30 months.

Classifications and definitions
-------------------------------

We classified ISS according to its location in a stent into four types : proximal, middle, distal, and diffuse types. ISS was defined when vessel diameter around implanted stent was decreased in follow-up angiography compared to the original diameter on immediate post-stenting angiography. Degrees of ISS were classified as mild stenosis (below 30% narrowing of parent artery), moderate (30% to 50%), and severe (above 50% narrowing). Statistical comparisons of group clinical characteristics were conducted for the total population. Multiple medical risk factors were defined when patient had more than two risk factors among four medical risk factors (hypertension, DM, dyslipidemia, and smoking).

Statistical analysis
--------------------

Univariate analysis was used to identify factors affecting ISS. Chi-square test or Fisher's exact test was used to analyze categorical variables while independent t-test was used for continuous variables. All statistical analyses were performed using SPSS version 23.0.0. (IBM, Armonk, NY, USA) Statistical significance was accepted at *p*\<0.05.

RESULTS
=======

Demographic characteristics of all subjected used in this study are summarized in [Table 1](#t1-jkns-2019-0087){ref-type="table"}. Their mean age was 51.69 years (range, 30 to 80 years). Of 120 patients, 32 were men and 88 were women. Of 123 aneurysm, mean aneurysm size was 6.0 mm (range, 2.1 to 28.3 mm) and the mean size of the aneurysm neck was 3.6 mm (range, 1.1 to 9.2 mm). Multiple stenting was performed for seven cases (5.7%). Procedural complication such as intra-procedural rupture or thromboembolic event occurred in 10 cases (8.1%). Ruptured aneurysms occurred in 84 cases (68.3%), including 56 cases (45.5%) premedicated with dual anti-platelet. Sixty-three patients (52.5%) had hypertension. Ten (8.3%) had DM and eight (66.7%) had dyslipidemia. Sixteen patients (13.3%) continued to smoke cigarette after treatment. Twenty patients (16.7%) had multiple medical factors. The mean follow-up period was 54.14 months (range, 12 to 141 months).

Among 123 cases of aneurysm, 22 cases (17.9%) of ISS were revealed on follow-up angiography. Radiological and clinical characteristics of 22 ISS cases are shown in [Tables 2](#t2-jkns-2019-0087){ref-type="table"} and [3](#t3-jkns-2019-0087){ref-type="table"}. There were six men and 16 women with a mean age of 52.7 years (range, 37 to 71 years). The most common locations of aneurysm were anterior communicating artery (AcomA, six cases) and bifurcation of middle cerebral artery (MCA, six cases). Multiple stenting was performed in three cases (13.6%) and intra-procedural rupture occurred in two cases (9.1%). Most cases were asymptomatic and symptomatic stenosis (transient ischemic attack) was identified in only one case. Sixteen cases (68.3%) were ruptured aneurysm. Mild stenosis was observed in 11 cases (50.0%). Moderate stenosis was found in eight cases (36.4%) and severe stenosis was identified in three cases (13.6%). Mean timing of identification of ISS was 8.90 months (range, 6 to 17 months). The most common type was proximal type (10 cases, 45.5%). Most cases were improved (12 cases, 54.5%) or not changed (nine cases, 40.9%) on follow-up angiography. Only one case was aggravated from mild stenosis to occlusion of parent artery (Case 15, [Fig. 1](#f1-jkns-2019-0087){ref-type="fig"}). Mean follow-up period was 44.3 months (range, 18 to 95 months).

We compared risk factors and characteristic between ISS group and non-ISS group using univariate analysis ([Table 3](#t3-jkns-2019-0087){ref-type="table"}). Proportion of ISS in small vessels such as AcomA and bifurcation of MCA was greater than that of others, however, there were no statistical significance (54.5% vs. 41.6% *p*=0.191). Multiple stenting was performed for three cases (13.6%) of the ISS group and four cases (4.0%) of the non-ISS group, showing no statistical difference between the two groups. Proportions of procedural complication, ruptured state, and premedication of dual antiplatelet before treatment were also similar between the two groups. Although the proportion of patients who had a history of hypertension, DM, dyslipidemia, or smoking in the ISS group was higher than that in the nonISS group, the difference between the two groups was not statistically significant. Additionally, the proportion of patients who had more than two risk factors among four medical risk factors (hypertension, DM, dyslipidemia, and smoking) was higher in the ISS group than that in the non-ISS group, the difference between the two was not statistically significant either (31.8% vs. 12.9%, *p*=0.05).

Case illustration
-----------------

### Case 15

A 49-year-old female had a ruptured aneurysm and experienced a severe headache. Patient had history of hypertension, DM, smoking, and stenting for coronary artery stenosis. A saccular aneurysm on the left bifurcation of MCA was treated by stent-assisted coil embolization with Neuroform 3 stent. Immediate post-embolization angiography showed nearly completely occluded aneurysm without any lesion around the stent ([Fig. 1A](#f1-jkns-2019-0087){ref-type="fig"}). However, mild ISS in the proximal portion of stent was revealed on follow-up angiography 6 months later ([Fig. 1B](#f1-jkns-2019-0087){ref-type="fig"}). Post-embolization 12-month angiography showed an occlusion of MCA from the portion of ISS ([Fig. 1C](#f1-jkns-2019-0087){ref-type="fig"}). She was unable to quit smoking at that time. Final angiography was performed at post-embolization 65 months and angiographic finding was not changed. Fortunately, she had no symptom associated with the obstruction of MCA. Her clinical course has been uneventful during the period of follow-up.

### Case 17

A 56-year-old female patient had incidental right bifurcation of MCA aneurysm. She had medical histories of hypertension and dyslipidemia. Stent-assisted coil embolization using Neuroform 3 stent was performed for the aneurysm. The stent was deployed from M1 to M2. Well-occluded aneurysm without in-stent complication was seen on immediate post-embolization angiography ([Fig. 2A](#f2-jkns-2019-0087){ref-type="fig"}). The patient experienced transient weakness of the left arm and dysarthria 6 months later. Angiography showed severe ISS (\>50%) in the proximal portion of the implanted stent ([Fig. 2B](#f2-jkns-2019-0087){ref-type="fig"}). After Plavix and Atorvastatin were added into her prescription, a recovery from severe to mild stenosis was identified on follow-up angiography at 28 months post embolization ([Fig. 2C](#f2-jkns-2019-0087){ref-type="fig"}). She have not experience transient ischemic symptom again.

DISCUSSION
==========

[Table 4](#t4-jkns-2019-0087){ref-type="table"} shows characteristics and follow-up data of ISS after stenting with Neuroform or Enterprise stent according to published literatures. They have some differences depending on ISS rate, kinds of follow-up, kinds of stents, and criteria of ISS. Incidence rates of ISS and symptomatic stenosis after SAC have been reported to be 2.3--7.8% and 0--1.3%, respectively \[[@b4-jkns-2019-0087],[@b9-jkns-2019-0087],[@b12-jkns-2019-0087],[@b18-jkns-2019-0087],[@b22-jkns-2019-0087],[@b25-jkns-2019-0087]\]. According to literatures, ISS rates after Neuroform stenting are relatively low, ranging from 0% to 6.3% \[[@b1-jkns-2019-0087],[@b4-jkns-2019-0087],[@b8-jkns-2019-0087],[@b17-jkns-2019-0087],[@b24-jkns-2019-0087]\]. ISS rate in our study was revealed to be 17.9%, which was relatively higher than rate in other studies. Significant ISS was defined as above 50% stenosis in most studies \[[@b9-jkns-2019-0087],[@b12-jkns-2019-0087],[@b13-jkns-2019-0087],[@b18-jkns-2019-0087]\] or classified as 33.3% and 66.6% stenosis in some studies \[[@b5-jkns-2019-0087],[@b7-jkns-2019-0087]\]. Considering that our criterion of ISS was below 30% stenosis, our incidence (17.9%) would be reasonable. Additionally, Case 15 ([Fig. 1](#f1-jkns-2019-0087){ref-type="fig"}) showed that even mild ISS (below 30%) stenosis could be aggravated to occlusion. Thus, mild or moderate ISS could be clinically significant. In another study with similar criterion \[[@b5-jkns-2019-0087]\], the ISS rate after LVIS stent-assisted coiling was 86.7%. This result showed that the ISS rate could be variable depending on kinds of stent because greater surface area coverage and smaller cell-size of stents could be risk factors of ISS \[[@b3-jkns-2019-0087],[@b5-jkns-2019-0087],[@b20-jkns-2019-0087]\].

Spontaneous resolution of the stenosis has also been observed in several case reports with a rate of 12.5--66.6% \[[@b9-jkns-2019-0087],[@b13-jkns-2019-0087],[@b18-jkns-2019-0087],[@b25-jkns-2019-0087]\]. Some authors have suggested that aneurysmal stenting seems to have a more benign course than atherosclerosis based on the rate of adverse events and spontaneous resolution \[[@b11-jkns-2019-0087],[@b15-jkns-2019-0087],[@b16-jkns-2019-0087]\]. In addition, Gao et al. \[[@b10-jkns-2019-0087]\] have suggested that ISS might be dynamic and spontaneously resolvable. They presented evidence indicating that stenosis peaked at 4--6 months following the procedure, but resolved at 12--24 months post-treatment. However, most studies had small number of cases (range, 1 to 9 cases) and short-term or mid-term follow-up period (range, 6 to 33 months). In addition, continuity of follow-up appeared to be lacking. Thus, we tried to identify a change in ISS from formation to final result during the follow-up period. Our mean follow-up period was 44.3 months, ranging from 18 to 95 months in 22 cases. We checked changes of ISS sequentially for a relatively long-term. Ultimately, we found that most cases were improved (12 cases, 54.5%) or not changed (nine cases, 40.9%) on follow-up angiography. Only one case was aggravated from mild stenosis to occlusion of parent artery. Although the prognosis of ISS is benign, physicians should focus on aggravation cases because all ISS cases have potential to aggravate. Whether asymptomatic stenosis could be changed to asymptomatic or symptomatic aggravation of stenosis in follow-up is unknown. Our results suggest that special attention and follow-up are needed for ISS.

In most studies, both magnetic resolution angiography (MRA) with time of flight (TOF) technique or contrast enhancement (CE) and catheter selected angiography are used to identify IIS through radiologic follow-up \[[@b9-jkns-2019-0087],[@b13-jkns-2019-0087],[@b17-jkns-2019-0087],[@b24-jkns-2019-0087]\]. Many endovascular surgeons have their own protocols of image follow-up after endovascular coiling for intracerebral aneurysm depending on their experience and situation of their institute. We did at least three times of follow-up cerebral angiography using digital subtraction angiography (DSA) for 3 to 4 years. Some physicians have suggested the usefulness of MRA using TOF technique or CE for follow-up \[[@b14-jkns-2019-0087],[@b23-jkns-2019-0087]\]. Most physicians might have performed follow-up imaging using both techniques. Follow-up using DSA has been chosen as the only method in our institute because DSA could is still a gold standard and promising technique for cerebral disease, although Prabhakaran et al. \[[@b21-jkns-2019-0087]\] have suggested that MRA could be a promising screening test to detect intracranial in-stent stenosis. Because only one type of radiologic technique was used in our study, we were able to collect constant image and prove differences of angiographic change more accurately.

The degree of neo-intimal hyperplasia and ISS after SAC is probably linked to the severity of endothelial injury induced during stent deployment and further manipulations that can affect stent stability during the initial procedure \[[@b13-jkns-2019-0087]\]. Recent multicenter studies focusing on aneurysm occlusion after Ystenting has reported that immediate total or near total occlusion is achieved in a high rate of cases \[[@b5-jkns-2019-0087],[@b6-jkns-2019-0087]\]. Multiple stenting is a very meticulous and high-skilled technique comparing with simple stenting. It can result in intimal injury easily. In our study, multiple stenting was performed in three cases (13.6%) of the ISS group and four cases (4.0%) in the non-ISS group. Although the rate of multiple stenting performed showed discrepancy between the two groups, the difference was not statistically significant. Larger samples size with prospective study design is needed to obtain a definite conclusion. SAH by itself could be a vulnerable condition to form ISS. The intracerebral hemodynamics might be unstable and patient might be in hypercoagulable state \[[@b13-jkns-2019-0087]\]. Additionally, physician's understanding about vascular geometry around aneurysm for ruptured cases might be lower than that for unruptured cases because most ruptured cases were in emergent situation. However, there was no significant difference in SAH or premedication rate between ISS and non-ISS groups in our study. Although the tortuosity of vasculature was excluded from our study as a risk factor because it was difficult to quantify a tortuosity objectively, the tortuosity of vasculature might be a potential risk factor affecting intimal injury from stenting. In addition, medical condition and smoking might be risk factors related to repair mechanism. This is because metabolic syndrome such as hypertension, DM, dyslipidemia, and smoking are well-known risk factors of atherosclerosis and instent stenosis of stenting for atherosclerotic disease \[[@b2-jkns-2019-0087],[@b19-jkns-2019-0087]\]. However, we failed to prove a difference in medical risk factor ratio between ISS and non-ISS groups. Although the proportion of patients with multiple medical factor (over two factors among hypertension, DM, dyslipidemia, and smoking) did not show statistically significant difference between the two groups (*p*=0.05), it showed a tendency to have relations with the occurrence of ISS. Multiple factors and complex mechanism could influence the formation of ISS. Our results suggest that it might be better to control medical co-morbidities and quit smoking for ISS prevention after treatment.

The present study has some limitations. First, it was performed using a retrospective chart review. This situation might have increased the risk of selection bias. Second, the number of patients enrolled in this study was too small to reach statistically significant conclusions. A future study with a larger number of patients is needed to establish risk factors of ISS. Despite these limitations, our study might provide guidance for planning treatment strategy when physicians encounter a similar situation.

CONCLUSION
==========

Clinical course and long-term prognosis of ISS might be benign. Most cases of ISS could be improved or not aggravated. Control of medical co-morbidity might be important. To the best of our knowledge, our study had more cases with longer follow-up period of time than other reports.
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![Aggravated case of ISS (Case 15). A : Immediate post-embolization angiography shows nearly completely occluded aneurysm without any lesion around the stent. B : Mild ISS in the proximal portion of stent is revealed on follow-up angiography 6 months later. C : Post-embolization 12-month angiography shows an occlusion of middle cerebral artery from the portion of ISS. ISS : in-stent stenosis.](jkns-2019-0087f1){#f1-jkns-2019-0087}

![Improved cases of ISS (Case 17). A : Well-occluded aneurysm without in-stent complication is seen on immediate post-embolization angiography. B : Angiography shows severe ISS (\>50%, white arrowheads) in the proximal portion of the implanted stent. C : A recovery from severe to mild stenosis (black arrowheads) is identified on follow-up angiography at 28 months post embolization. ISS : in-stent stenosis.](jkns-2019-0087f2){#f2-jkns-2019-0087}

###### 

Demographic characteristics of all subjected (n=123)

                                 Value
  ------------------------------ -----------
  Mean age (years)               51.69
  Female                         88 (71.5)
  Mean size (mm)                 6.03
  Mean neck (mm)                 3.55
  Multiple stenting              7 (5.7)
  Procedural complication        10 (8.1)
  Ruptured state                 84 (68.3)
  Pre-medication                 56 (45.5)
  HTN                            63 (51.2)
  DM                             10 (8.1)
  Dyslipidemia                   8 (6.5)
  Smoking                        16 (13.0)
  Multiple medical factors       20 (16.3)
  Mean last follow-up (months)   54.14

Values are presented as number (%). HTN : hypertension, DM : diabetes mellitus

###### 

Radiological and clinical characteristics of 22 ISS cases

  No   Age   Sex   Location   Kinds of stent   Complication   Sx.   Ruptured     Degree     Type       Timing   prognosis     Final f/u   Past Hx
  ---- ----- ----- ---------- ---------------- -------------- ----- ------------ ---------- ---------- -------- ------------- ----------- -----------------------
  1    49    M     AcomA      Neu3             0              No    Ruptured     Mild       Diffuse    12       Improved      24          HTN
  2    37    M     AcomA      Enter            0              No    Ruptured     Severe     Distal     12       Not changed   23          HTN, smoking
  3    57    F     AcomA      Neu3             0              No    Ruptured     Moderate   Distal     6        Not changed   30          No
  4    52    F     AcomA      NeuEz            0              No    Ruptured     Mild       Distal     6        Improved      34          No
  5    41    F     AcomA      NeuEz            R              No    Ruptured     Moderate   Proximal   6        Improved      38          HTN
  6    57    F     AcomA      NeuEz            0              No    Ruptured     Mild       Distal     6        Not changed   30          HTN
  7    58    M     PcomA      Neu3             0              No    Ruptured     Moderate   Proximal   17       Not changed   31          DM, HTN
  8    56    F     Opthal.    Neu3             0              No    Unruptured   Mild       Proximal   6        Not changed   53          HTN
  9    59    F     PcomA      Enter            0              No    Unruptured   Moderate   Distal     13       Not changed   63          HTN
  10   51    F     Opthal.    NeuroformEz      0              No    Ruptured     Mild       Distal     6        Not changed   42          HTN
  11   70    F     PcomA      NeuroformEz      0              No    Ruptured     Mild       Middle     15       Improved      40          HTN, smoking
  12   49    M     MCAbif     Neu3+Neu3        R              No    Ruptured     Moderate   Proximal   12       Not changed   65          HTN
  13   71    F     MCAbif     Neu3             0              No    Unruptured   Mild       Diffuse    12       Improved      65          DM, HTN, dyslipidemia
  14   48    M     MCAbif     Neu3             0              No    Ruptured     Moderate   Proximal   12       Improved      37          No
  15   49    F     MCAbif     Neu3             0              No    Ruptured     Mild       Proximal   6        Aggravated    65          DM, HTN, smoking
  16   52    F     MCAbif     Neu3+Enter       0              No    Ruptured     Severe     Proximal   6        Improved      18          HTN
  17   56    F     MCAbif     Neu3             0              TIA   Unruptured   Severe     Proximal   6        Improved      28          Dyslipidemia, HTN
  18   66    F     SCA        Neu3             0              No    Ruptured     Mild       Distal     6        Not changed   95          HTN
  19   47    F     PICA       Neu3             0              No    Ruptured     Moderate   Distal     13       Improved      38          No
  20   41    M     BT         Neu3             0              No    Unruptured   Mild       Proximal   6        Improved      86          DM, smoking
  21   50    F     VA         Neu3+NeuEz       0              No    Unruptured   Mild       Proximal   6        Improved      32          HTN
  22   44    F     VA         Neu3             0              No    Ruptured     Moderate   Middle     6        Improved      37          No

ISS : in-stent stenosis, Sx. : symptom, f/u : follow-up, Hx : medical history, M : male, AcomA : anterior communicating artery, Neu3 : Neuroform3, HTN : hypertension, Enter : Enterprise, F : female, NeuEz : NeuroformEz, R : procedural rupture, PcomA : posterior communicating artery, Opthal. : opthalmic artery, MCAbif : bifurcation of Middle cerebral artery, SCA : stent assisted coiling, PICA : posterior inferior cerebral artery, BT : basilar top, VA : vertebral artery

###### 

Comparison of risk factors and characteristic between ISS group and non-ISS group

                             ISS (n=22)   Non-ISS (n=101)   *p*-value
  -------------------------- ------------ ----------------- -----------
  Age \>55 years             9 (40.9)     39 (38.6)         1.000
  Female                     16 (72.7)    72 (71.3)         1.000
  AcomA & MCAbif aneurysm    12 (54.5)    42 (41.6)         0.191
  Multiple stenting          3 (13.6)     4 (4.0)           0.108
  Procedural complication    2 (9.1)      8 (7.9)           1.000
  Ruptured state             16 (72.7)    68 (67.3)         0.801
  Pre-medication             9 (40.9)     47 (46.5)         0.101
  HTN                        16 (72.7)    47 (46.5)         0.101
  DM                         4 (18.2)     6 (5.9)           0.078
  Dyslipidemia               2 (9.1)      6 (5.9)           0.633
  Smoking                    4 (18.2)     12 (11.9)         0.484
  Multiple medical factors   7 (31.8)     13 (12.9)         0.05

Values are presented as number (%). ISS : in-stent stenosis, AcomA : anterior communicating artery, MCAbif : middle cerebral artery bifurcation, HTN : hypertension, DM : diabetes mellitus

###### 

Characteristics and follow-up data of ISS after stenting in literatures

  No.   Study                                               Kinds of follow-up   Kinds of stent          Criteria of ISS   ISS rate       Symptom              Progress       Follow-up period of time
  ----- --------------------------------------------------- -------------------- ----------------------- ----------------- -------------- -------------------- -------------- --------------------------
  1     Biondi et al. \[[@b4-jkns-2019-0087]\] (2007)       DSA                  Neuroform               No data           1/42 (2.4%)    Asymtomatic          No data        Mean 9 month
  2     Fiorella et al. \[[@b9-jkns-2019-0087]\] (2006)     MRA, DSA             Neuroform               \>50%             9/161 (5.6%)   2/9 (symptomatic)    1/9 progress   14 to 17 month
  3     Kanaan et al. \[[@b12-jkns-2019-0087]\] (2010)      DSA                  Neuroform, Enterprise   \>50%             5/133 (3.8%)   2/5 (asymptomatic)   No data        Mean 15.4 month
  4     Kulcsár et al. \[[@b13-jkns-2019-0087]\] (2013)     MRA, DSA             Neuroform               \>50%             3/117 (2.6%)   Asymtomatic          2/3 improved   Mean 33 month
  5     Maldonado et al. \[[@b17-jkns-2019-0087]\] (2011)   DSA, MRA             Neuroform               No data           3/76 (3.9%)    Asymtomatic          No data        Mean 25.7 month
  6     Mocco et al. \[[@b18-jkns-2019-0087]\] (2011)       DSA                  Enterprise              \>50%             3/110 (2.7%)   Asymtomatic          1/3 improved   Mean 175 days
  7     Vendrell et al. \[[@b24-jkns-2019-0087]\] (2011)    MRA, DSA             Neuroform, Enterprise   No data           2/47 (4.3%)    Asymtomatic          No data        No data
  8     Yoon and Kim\[[@b25-jkns-2019-0087]\] (2010)        DSA                  Neuroform, Enterprise   \>20%             8/102 (7.8%)   Asymtomatic          1/8 improved   No data

ISS : in-stent stenosis, DSA : digital subtraction angiography, MRA : magnetic resolution angiography
